1. Home
  2. News
  3. Alterity Therapeutics Ltd.
  4. Regulatory approval for Phase II trial in France and Austria
More Alterity Therapeutics Ltd. news
Alterity Therapeutics Ltd.ASX: ATH

Regulatory approval for Phase II trial in France and Austria

Feb 16, 2023 at 1:51 AM EST · Issued by Alterity Therapeutics Ltd.

Filed with ASX · Feb 16, 2023 at 1:51 AM EST · 3 pages · English

On 6ix: 6ix.com/news/regulatory-approval-for-phase-ii-trial-in-france-and-austria

Alterity Therapeutics Ltd. on 6ix

Earlier from Alterity Therapeutics

  • ATH434 Clinical Trial Launched in ItalyJan 24, 2023
  • ATH434 clinical trial launched in the USJan 9, 2023
  • New US patent for compounds to treat neurodegenerationDec 29, 2022
  • ATH434 Clinical Trial launched in AustraliaOct 13, 2022
  • US FDA Approval for IND Application for ATH434 for MSASep 19, 2022

Later from Alterity Therapeutics

  • First Patient Enrolled in Europe in Phase II Clinical trialMar 7, 2023
  • US patent grant and license agreementMar 14, 2023
  • Appendix 4C and Quarterly Cash Flow ReportApr 27, 2023
  • ATH starts 2nd Phase 2 Study in Rare Parkinsonian DisorderMay 30, 2023
  • Investor PresentationJun 22, 2023
All Alterity Therapeutics news releases↗

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer